TextSearch

Pioneering innovative new treatments for patients with neurological diseases Learn More about OUR Pipeline Targeting the metabolic basis of diseases of the brain Learn More about OUR Science A world-class team of drug developers focused on addressing huge areas of unmet medical need Learn More About OUR Technology Unparalleled experience and knowledge in complex formulations and lipid-drug development Learn More about Us Latest News 1 / 10 Cerecin Announces Publication of Clinical Study Demonstrating Promising Results of CER-0001 (tricaprilin) for Rare Pediatric Epilepsy 26 February 2026 View More The Potential of Fasting and Diet in the Future of Medicine 24 February 2026 View More Cerecin Joins NIHR HealthTech Research Centre in Brain Health as an Industry Partner 26 August 2025 View More Cerecin Signs an MOU with Cha Bundang Hospital 05 April 2025 View More Cerecin Expands Leadership Team with Appointment of Chief Medical Officer and Chief Operating Officer 01 September 2024 View More Cerecin Bolsters Pipeline with a Strategic Acquisition From Boston Scientific 01 January 2024 View More Cerecin forges strategic partnership with A*STAR's Institute of Molecular and Cell Biology (IMCB) in Singapore to advance R&D in neurological disorders 1 December 2023 View More Cerecin strengthens position in neurometabolism with addition to pipeline 19 September 2023 View More Cerecin to Present New Infantile Spasms Data at the 35th Interna1onal Epilepsy Congress, Dublin 2023 30 August 2023 View More Clinical Trial Data of Novel Metabolic Mechanism in Migraine: CER-0001, a Ketogenic Investigational Agent 30 June 2023 View More Our Partners

Cerecin NeurosciencesCerecin Neurosciences